aspect of
drug)
→
ReceivesAction
→
demonstrated in vitro
| Typicality: | 0.300 |
| Saliency: | 0.118 |
| with tetracycline | 3 | other |
| in patients with myeloid malignancies | 2 | other |
| effect → be demonstrated in → vitro | 3 |
| effect → be observed in → vitro | 3 |
| negative | neutral | positive |
| 0.210 | 0.688 | 0.103 |
| Raw frequency | 6 |
| Normalized frequency | 0.118 |
| Modifier score | 0.500 |
| Perplexity | 20.399 |